modelC03DA01

Diagram of C03DA01

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Spironolactone
ATC code:C03DA01
route:oral
compartments:1
dosage:100mg
volume of distribution:13.3L
clearance:20.1L/h
other parameters in model implementation

Spironolactone is a potassium-sparing diuretic and an antagonist of aldosterone. It is primarily used to treat conditions such as heart failure, hypertension, primary hyperaldosteronism, and edema associated with liver cirrhosis or nephrotic syndrome. It is also used for treatment of hirsutism and acne in women. Spironolactone is an approved drug and is commonly used in clinical practice today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.

References

  1. Lass, J, et al., & Lutsar, I (2024). Pharmacokinetics of oral spironolactone in infants up to 2 years of age. European journal of clinical pharmacology 80(2) 239–248. DOI:10.1007/s00228-023-03599-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/38041740

  2. Oishi, M, et al., & Sweeney, K (2017). Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. Journal of clinical pharmacology 57(6) 730–738. DOI:10.1002/jcph.861 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28032902

  3. Chen, R, et al., & Xia, ZL (2013). Population pharmacokinetics of digoxin in elderly patients. European journal of drug metabolism and pharmacokinetics 38(2) 115–121. DOI:10.1007/s13318-012-0107-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23096939

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)